The UK pharma group fought Pfizer's $120 billion bid by promising growth. But its defence has been aided most by U.S. curbs on tax-driven M&A, says Reuters Breakingviews.
01:07
01:30
01:01
00:50
01:58
01:13
01:10
01:03
01:21
01:04
01:06
00:45
01:26
02:12
01:56
01:45
00:58
01:34
01:36
01:43
01:30
01:13
01:38
01:23
01:21
01:09
02:37
02:33
02:55
02:27
01:44
00:31
01:22
01:10
01:01
01:05
02:00
01:29
01:06
01:41
01:06
01:09
01:29
01:01
02:39
01:22
01:08
01:03
01:50
01:21
01:04
01:06
01:30
00:58
01:02
01:02
01:41
01:09
01:10
01:14
01:22
04:51
02:06
01:01
01:05
01:22
01:21
01:13
01:33
01:16
05:03
01:13
00:57
01:21
00:52
01:23
00:59
01:03
01:58
01:38
01:50
02:02
02:02
01:16
01:26
01:26
01:01
02:52
01:45
01:08
01:19
01:16
00:49
01:01
01:24
02:20
00:49
02:04
01:22
00:36
01:28
03:40
01:05
01:15
01:28
01:24
01:50
02:10
01:14
02:04
01:04
01:53
01:14
01:08
01:34
01:34
01:19
01:31
01:59
00:38